Researchers from Taiwan analyzed data from more than 3 million patients with obesity in the TriNetX Global Network between Jan. 1, 2016 and March 31, 2024. Of those patients, 12,123 individuals who received GLP-1 medication were matched with the same number of individuals who had not received it.
Patients who received the medication had a significantly lower risk of mortality, ischemic heart disease, heart failure, arrhythmias, hypertension, stroke and atrial fibrillation, according to the study.
Jeffrey Wessler, MD, a cardiologist with New Hyde Park, N.Y.-based Northwell Health, shared his perspective on GLP-1s and patient adherence with Becker’s earlier in August.
“There are certainly some downstream issues with GLP-1s,” he said. “But for adherence, which is a prime issue for many cardiac medications that work really well in a clinical trial setting, that is not really an issue. People want to take it. It is really transforming how I think about managing an early stage cardiometabolic patient.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
